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and erythrocyte ribavirin levels in predicting SVR in HCV genotype-1
patients undergoing peginterferon + ribavirin treatment.
Material and methods: 30 HCV genotype-1 patients (22M/8F mean
age 45,2±13,6 yrs) undergoing a standard treatment schedule (Peg-IFN
180 mcg weekly+ribavirin 1000 or 1200 mg daily, according to bw)
were included in the study. Plasma and erythrocyte ribavirin levels
were evaluated in all patients at week 12. At week 24 ribavirin lev-
els were re-assessed in those obtaining EVR. Ribavirin concentration
was evaluated by high performance liquid chromatography employing
3-methyl-cytidine as internal standard.
Results: Twenty-five patients (82%) obtained EVR, while sixteen
(53%) achieved SVR. There was no difference among EVR and non
EVR patients in terms of serum and erythrocyte ribavirin concentration
at week 12. At week 24, EVR patients obtaining SVR exhibited higher
levels of ribavirin in serum and lower in erythrocytes, in comparison
with non SVR patients (serum 14,1±10,5 vs 5,9±4,1 μM; p<0.02;
erythrocyte 1072±420 vs 1793±903 μM; p<0.02). When [serum rib-
avirin]/[erythrocyte ribavirin] × 100 ratio was compared, the difference
was enhanced (1,6±1,5 vs 0,4±0,34; p <0.01). ROC curve analysis
identified a cut-off for [serum ribavirin]/ [erythrocyte ribavirin] × 100
ratio in predicting SVR of 0,6, with a NPV of 80% and a PPV of 85%,
while those related to EVR were 100% and 63%, respectively.
Conclusions: [serum ribavirin]/[erythrocyte ribavirin] × 100 ratio at
week 24 seems to be an 85% indicator of SVR in genotype-1 patients
obtaining EVR. Whether drug adjustment, according to this parameter,
might be useful to increase SVR remains speculative.
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Background and aim: Anemia during Pegylated Interferon (PegIFN)/
Ribavirin (Rbv) therapy is attributed to the haemolytic effect of Rbv
concentrated into erythrocytes. However, biomarkers of haemolysis are
not altered in parallel in all patients. Aim We therefore compared the
pattern of haemolysis and erythropoiesis in patients receiving PegIFN
alone or combined with Rbv.
Material and methods: 18 patients with chronic HCV-2 infection
consecutively receiving PegIFN-α2a 180 mcg/week plus Rbv 800
mg/day for 24 weeks were compared to 10 patients with chronic
hepatitis B, consecutively receiving PegIFN-α2a 180 mcg/week for
48 weeks. Haemolysis was investigated by serum LDH, haptoglobin
and reticolocyte count; erythropoiesis by peripheral erythroid progen-
itors cell coltures (BFUe and CFU-GEMM) and gene expression of
gamma-globin and GATA2 by quantitative real-time PCR. The effects
of PegIFN-α2a and Rbv added at day 0 and 7 to blood coltures ob-
tained from healthy volunteers on erythroid progenitor cellular growth,
cell differentiation and gene expression of glycoforin A were also
investigated.
Results: A sharper and faster decrease of Hb, indicative for haemolysis
was seen in 3 (11%) HCV patients, only (Hb decrease at week 4:
3.40 vs 1.55 g/dL, p=0.01), with an increase of BFUe at week 4 of
therapy (7.723 to 25.0/105 cells) as a likely response to peripheral
haemolysis. At week 4 the 15 non hemolytic HCV patients and the
HBV patients showed a significant reduction in BFUe number (HCV:
13.588 to 5.737/105 cells; HBV: 17.226 to 5.942/105 cells) with an
increase in undifferentiated CFU-GEMM colony formation (HCV: 1.97
to 2.78/105 cells; HBV: 1.7 to 3.3/105 cells) indicative of inhibition of
erythroid differentiation by PegIFN/Rbv, confirmed also by increased
expression of primitive erythropoiesis specific genes like gamma-globin
(5.1 fold) and GATA2 (4.69 fold). In vitro analysis showed that both
PegIFN and Rbv inhibit cell proliferation and differentiation with a
50% reduction of cellular growth and 47% of glycoforin A expression
vs control, confirmed by cell morphology analysis.
Conclusions: These observations suggest suppression of erythroid dif-
ferentiation to cause anemia during PegIFN/Rbv therapy, while Rbv
itself may cause myelosuppression.
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Background and aim: The mechanisms for progression of liver injury
towards hepatic fibrosis in chronic hepatitis C (HCV) are unknown.
Insulin resistance (IR) is an independent predictor of HCV-related
fibrosis. A ductular reaction (DR) occur during chronic liver injury
and represents a potential profibrogenic mechanism by the recruitment
of myofibroblasts and by undergoing epithelial-mesenchymal transition
(EMT). Aim of the study was to evaluate: a) the relationship between
IR, the degree of liver injury and DR; b) the ability of DR to stimulate
fibrogenesis in HCV.
Material and methods: 78 consecutive HCV patients underwent liver
biopsy and IR evaluation by the oral glucose insulin sensitivity (OGIS)
test. Liver injury was determined by Ishak’s score, and immunohisto-
chemistry perfomed for citokeratin-7 (CK7, a marker of DR), αSMA
(marker of activated hepatic stellate cell, HSC), and S100A4 (EMT
marker).
Results: IR (OGIS<9.8 mg/kg/min) was associated with aggregate
hepatic inflammatory activity (p<0.01) and its individual components
of piecemeal necrosis (p<0.05), confluent necrosis (p<0.05), and por-
tal inflammation (p<0.005), as well as the degree of hepatic fibrosis
(p<0.001). In the portal tract, CK7-positive cells appeared as elements
of the DR (Ø < 6 um) or intermediate hepatobiliary cells (IHC, Ø <40
m), while at the interface they also showed a stellate-like fibroblastic
appearance. DR was observed in all HCV, while IHC were detected only
in 38% of cases (grading > 8 and staging > 3). IR correlated with an
expansion of DR (p < 0.02) and a larger number of IHC (p < 0.05). DR
and IHC were associated with the total grading, HSC activation (αSMA
expression), and hepatic staging (p < 0.001). S100A4 expression was
well evident in elements of the DR. By dual immunofluorescence and
morphometry, S100A4/CK7 co-localization significantly increased with
the progression of liver injury (p < 0.05). By multivariate analysis, IR
and total inflammation were the only independent predictors of hepatic
fibrosis.
Conclusions: In conclusion: a) IR determines a higher degree of
necroinflammatory liver injury in HCV; b) this leads to enhancement
